gms | German Medical Science

27th German Cancer Congress Berlin 2006

German Cancer Society (Frankfurt/M.)

22. - 26.03.2006, Berlin

Protein Microarrays in Tumour Diagnosis

Meeting Abstract

Search Medline for

27. Deutscher Krebskongress. Berlin, 22.-26.03.2006. Düsseldorf, Köln: German Medical Science; 2006. DocIS109

The electronic version of this article is the complete one and can be found online at:

Published: March 20, 2006

© 2006 Wingren.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.



Protein microarrays, and in particular antibody-based microarrays, are among the novel class of rapidly evolving proteomic technologies that holds great promise in biomedicine. Miniaturized microarrays (< 1 cm2) can be printed with thousands of e.g. individual antibodies carrying the desired specificities, and with biological sample (e.g. an entire proteome) added, virtually any specifically bound analytes can be detected. While consuming only minute amounts (> pL scale) of the reagents, ultra-sensitive assays (zeptomol range) can readily be performed in a highly multiplexed manner. The microarray patterns generated can then be transformed into proteomic maps, or detailed molecular fingerprints, revealing the composition of the proteome. Thus, protein expression profiling and global proteome analysis using this tool will offer new opportunities for cancer (disease) diagnostics, drug target and biomarker discovery, and insights into cancer (disease) biology. Adopting the antibody (protein) microarray technology platform, several biomedical applications, ranging from focused assays to semi proteome-scale analysis are rapidly emerging, especially within cancer proteomics. To date, major efforts have been placed upon detecting novel cancer biomarkers and differentially expressed set of proteins (i.e. cancer specific protein signatures) with a tremendous potential within cancer diagnostics. In our laboratory, we have successfully developed a high-performing antibody microarray technology platform based on recombinant antibody fragments with the long-term goal to perform high-throughput cancer proteomics. In this presentation, I will present the current status of the antibody (protein) microarray technology and its current and future biomedical applications, with a particular focus on cancer proteomics and tumour diagnosis.


Wingren C, Borrebaeck CAK. High-throughput proteomics using antibody microarrays. Expert Rew Proteomics. 2004;1:358-64.